Nordic Issuing

Ongoing case

Prostatype Genomics AB

Back to all cases

Prostatype Genomics AB

6 Jul - 20 Jul 2022Rights issue

Prostatype Genomics AB manufactures, markets and sells the prognostic gene test Prostatype.
By giving a comprehensive assessment of the aggressiveness of the prostate cancer, Prostatype helps clinicians and patients to make correct treatment decisions. Over and under treatment of prostate cancer can be minimized, the quality of life for the patient improved and money can be saved for the health care sector.

Read more at the company's website

The offer in summary

Record date: 30 June 2022

Subscription period: 6 July - 20 July 2022

Subscription rights: Anyone who were shareholder in the Company on the record date of June 30, 2022 has a preferential right to subscribe for units in the rights issue in relation to previous holdings, whereby one (1) existing share gives one (1) unit rights. Thirty seven (37) unit rights entitle to subscribe for one (1) new unit.

Price: 55.10 SEK per unit

The offer: 408 205 units

Trading with rights: 6 July - 15 July 2022

Market Place : Nasdaq First North Growth Market

Financial advisor: Sedermera Corporate Finance

Subscribe through Avanza here

Subscribe through Nordnet here


  Teaser Prospectus